Evaluation of Sleep Quality in Prostate Cancer Patients Undergoing Treatment With Hormonal Therapeutic Approaches and in Patients With Full-resected Early Breast Cancer

Inclusion Criteria for prostate cancer patients: * Written infor med consent according to International Conference on Harmonisation (ICH)/Good Clinical Practice (GCP) regulations before registration and prior to any trial specific procedures * Histologically proven adenocarcinoma of the prostate * Eastern Cooperative Oncology Group performance status 0-2 * Adult male patient \> 18 years of age, no upper age limit * Localized prostate cancer, locally advanced hormone-sensitive prostate cancer (HSPC) or metastatic hormone-sensitive prostate cancer (mHSPC) * ADT recipients are required to be scheduled to start ADT as standard of care (SOC) for metastatic or locally advanced prostate cancer * Scheduled to receive ADT treatment as SOC for \> 6 months in combination with radiotherapy or oral AR-targeted systemic treatment as prescribed by the treating physician or radiotherapy alone Exclusion Criteria for prostate cancer patients: * Histology with predominant small cell prostate cancer * Any previous treatment with ADT or oral AR-targeted agent (exception for short course anti-androgens - disease flare) * Have not received systemic treatment for any other cancer within the last 12 months * Active secondary malignancy that requires systemic therapy * Any clear contraindications present against treatment with ADT * Presence of sleep apnea syndrome, Apnea Hypopnea Index (AHI) \>15 at baseline * Body mass index (BMI) \> 35 at baseline * Severe respiratory disorders (asthma, Chronic …